Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
58.6M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
58.1M
-
Shares change
-
-3.48M
-
Total reported value, excl. options
-
$2.51B
-
Value change
-
-$113M
-
Put/Call ratio
-
1.07
-
Number of buys
-
96
-
Number of sells
-
-105
-
Price
-
$43.12
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) as of Q2 2024
250 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q2 2024.
AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.1M shares
of 58.6M outstanding shares and own 99.14% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (5.65M shares), VANGUARD GROUP INC (5.5M shares), BlackRock Inc. (4.86M shares), Bellevue Group AG (3.88M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.78M shares), Erste Asset Management GmbH (2.25M shares), DIMENSIONAL FUND ADVISORS LP (2.2M shares), STATE STREET CORP (2.11M shares), ARMISTICE CAPITAL, LLC (2.08M shares), and JPMORGAN CHASE & CO (1.78M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.